Cevostamab

立即咨询

Cevostamab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2249888-53-5

BFCR 4350A
RG 6160
RO 7187797

Cevostamab (BFCR4350A; RG6160; RO7187797) 是一种人源化、基于 IgG1 的 BsAb，可靶向多发性骨髓瘤 (MM) 细胞上FcRH5的近膜端胞外结构域，以及 T 细胞上的CD3。此外，Cevostamab 促进有效突触的形成，提高 T 细胞对 MM 肿瘤细胞的杀伤活性。

生物活性	Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain ofFcRH5on multiple myeloma (MM) cells as well asCD3on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells^[1]^[2].
IC₅₀& Target	FcRH5; CD3^[1]^[2]
体外研究 (In Vitro)	Cevostamab shows a dose-dependent and robust killing of B cells and bone marrow plasma cells from peripheral blood mononuclear cell (PBMC)/BMMC samples from cynomolgus monkey^[1].
体内研究 (In Vivo)	Cevostamab (0.5 mg/kg; i.v.; once weekly for ) suppresses the growth of established MOLP-2 tumors in mice reconstituted with human immune cells^[1].
CAS 号	2249888-53-5
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.